Tag Archives: cancer therapy

CREATE Medicines Rebrand From Myeloid Therapeutics Reflects Strategic Expansion into Multi-Lineage RNA Immunotherapy as Europe’s Biotech Sector Embraces In Vivo Therapies

Rebrand: Myeloid Therapeutics becomes CREATE Medicines, reflecting a shift to multi-lineage RNA immune programming. Scientific Focus: Expanding beyond myeloid cells to include T and NK cells for scalable, redosable in vivo CAR therapies. Clinical Data: Over 40 patients treated with … Read the full press release

Myeloid Therapeutics Rebrands as CREATE Medicines, Focused on Transforming Immunotherapy Through RNA-Based In Vivo Multi-Immune Programming

CREATE Medicines (“CREATE”) broadens clinical programs and capabilities to expand therapeutic potential and improve patient outcomes Therapies tolerably program immune cells inside the human body, providing clear differentiation among competitors and significant value potential for all stakeholders CREATE Medicines will … Read the full press release

Discovery of p21 redox switch reveals new mechanism controlling cell division and senescence in cancer research

(IN BRIEF) Scientists at the Institute of Cancer Research, London, together with colleagues from TUD Dresden University of Technology, have discovered that oxidation of a single site in the protein p21 acts as a chemical switch determining whether cells keep … Read the full press release

BioNTech to Showcase Advances in Cancer Therapy at ESMO Congress 2023

(IN BRIEF) BioNTech will be presenting updates on multiple programs across its oncology pipeline at the European Society for Molecular Oncology (ESMO) Congress 2023. These updates include data on investigational CAR-T and ex-vivo T cell therapies, a novel ADC (antibody-drug … Read the full press release

Leadership change at Siemens AG: long-serving President and CEO Joe Kaeser to step down after more than 40 years at the company

Annual Shareholders’ Meeting in virtual format due to corona pandemic Siemens bids farewell to Joe Kaeser after more than 40 years at the company Total shareholder return more than doubled since Kaeser took office in 2013 Roland Busch new President … Read the full press release